The Rabies Vaccine Market was valued at $1,207.03 million in 2022 and is estimated to reach $1,903.17 million by 2032, exhibiting a CAGR of 4.7% from 2023 to 2032.
Rabies is a virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. It is an illness that a person gets from an infection with the RABV virus. It causes symptoms such as seizures, hallucinations, and paralysis. The rabies vaccine is a vaccine used to prevent rabies. Moreover, there are several rabies vaccines available that are both safe and effective. They are used to prevent rabies before, and, for a period, after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.
The rabies vaccine market growth is driven by increase in prevalence of rabies, rise in initiatives taken by government, and surge in awareness regarding rabies vaccine. The incidence of rabies in animals and humans is a significant driver for the rabies vaccine market. In regions where rabies is endemic, there is a higher demand for rabies vaccines to prevent the spread of the disease. For instance, according to World Health Organization, (WHO), in September 2023, it was reported that, rabies is a vaccine-preventable viral disease which occurs in more than 150 countries and territories. It causes tens of thousands of deaths every year, mainly in Asia and Africa, 40% of whom are children under 15 years of age. Dogs are the main source of human rabies deaths, contributing up to 99% of all rabies transmissions to humans. Rabies can be prevented through vaccination of dogs and prevention of dog bites.
In addition, government-led rabies control and prevention programs often involve mass vaccination campaigns for animals and sometimes even free or subsidized vaccinations for humans who have been exposed to the virus. Government funding and support boost the market for rabies vaccines. Moreover, increased awareness about the risks of rabies and the importance of vaccination drive demand for rabies vaccines. Public health campaigns and educational efforts contribute to this awareness.
On the other hand, rabies vaccination, particularly post-exposure prophylaxis (PEP), is expensive. The high cost of treatment acts as a restraint, especially in regions with limited healthcare resources or where people are not able to afford the vaccine.
The rabies vaccine market is segmented into product type, prophylaxis type, application, end user, and region. By product type, the market is classified into chick embryo cells rabies vaccine, vero cell rabies vaccine, human diploid cell vaccine and others. Others includes purified duck embryo vaccine and baby hamster kidney (BHK) cells rabies vaccine. By prophylaxis type, the market is categorized into pre-exposure prophylaxis and post exposure prophylaxis. By application, the market is segmented into human and animal. By end user, the market is divided into hospitals, veterinary clinics, and others. Others segment includes vaccine centers and specialty clinics.
Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the global rabies vaccine market are Bharat Biotech International Limited, Zoetis, Sanofi, Boehringer Ingelheim International GmbH, Serum Institute of India Pvt. Ltd., Novartis AG, Cadila Pharmaceuticals, Merck & Co., Inc. Elanco Animal Health Incorporated., and Virbac SA. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their rabies vaccine market share.
Rabies is a virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. It is an illness that a person gets from an infection with the RABV virus. It causes symptoms such as seizures, hallucinations, and paralysis. The rabies vaccine is a vaccine used to prevent rabies. Moreover, there are several rabies vaccines available that are both safe and effective. They are used to prevent rabies before, and, for a period, after exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.
The rabies vaccine market growth is driven by increase in prevalence of rabies, rise in initiatives taken by government, and surge in awareness regarding rabies vaccine. The incidence of rabies in animals and humans is a significant driver for the rabies vaccine market. In regions where rabies is endemic, there is a higher demand for rabies vaccines to prevent the spread of the disease. For instance, according to World Health Organization, (WHO), in September 2023, it was reported that, rabies is a vaccine-preventable viral disease which occurs in more than 150 countries and territories. It causes tens of thousands of deaths every year, mainly in Asia and Africa, 40% of whom are children under 15 years of age. Dogs are the main source of human rabies deaths, contributing up to 99% of all rabies transmissions to humans. Rabies can be prevented through vaccination of dogs and prevention of dog bites.
In addition, government-led rabies control and prevention programs often involve mass vaccination campaigns for animals and sometimes even free or subsidized vaccinations for humans who have been exposed to the virus. Government funding and support boost the market for rabies vaccines. Moreover, increased awareness about the risks of rabies and the importance of vaccination drive demand for rabies vaccines. Public health campaigns and educational efforts contribute to this awareness.
On the other hand, rabies vaccination, particularly post-exposure prophylaxis (PEP), is expensive. The high cost of treatment acts as a restraint, especially in regions with limited healthcare resources or where people are not able to afford the vaccine.
The rabies vaccine market is segmented into product type, prophylaxis type, application, end user, and region. By product type, the market is classified into chick embryo cells rabies vaccine, vero cell rabies vaccine, human diploid cell vaccine and others. Others includes purified duck embryo vaccine and baby hamster kidney (BHK) cells rabies vaccine. By prophylaxis type, the market is categorized into pre-exposure prophylaxis and post exposure prophylaxis. By application, the market is segmented into human and animal. By end user, the market is divided into hospitals, veterinary clinics, and others. Others segment includes vaccine centers and specialty clinics.
Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the global rabies vaccine market are Bharat Biotech International Limited, Zoetis, Sanofi, Boehringer Ingelheim International GmbH, Serum Institute of India Pvt. Ltd., Novartis AG, Cadila Pharmaceuticals, Merck & Co., Inc. Elanco Animal Health Incorporated., and Virbac SA. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their rabies vaccine market share.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rabies vaccine market analysis from 2022 to 2032 to identify the prevailing rabies vaccine market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the rabies vaccine market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global rabies vaccine market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Product Benchmarking/Product specification and applications
- Upcoming/New Entrant by Regions
- New Product Development/Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Product Type
- Chick embryo cells rabies vaccine
- Vero cell rabies vaccine
- Human diploid cell vaccine
- Others
By Prophylaxis Type
- Pre-exposure prophylaxis
- Post-exposure prophylaxis
By Application
- Human
- Animal
By End User
- Hospitals
- Veterinary clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Serum Institute of India Pvt. Ltd.
- Sanofi
- Boehringer Ingelheim International GmbH
- Elanco Animal Health Incorporated.
- Virbac SA
- Novartis AG
- Cadila Pharmaceuticals Ltd
- Bharat Biotech International Limited
- Zoetis Inc.
- Merck & Co., Inc.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: RABIES VACCINE MARKET, BY PRODUCT TYPE
CHAPTER 5: RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE
CHAPTER 6: RABIES VACCINE MARKET, BY APPLICATION
CHAPTER 7: RABIES VACCINE MARKET, BY END USER
CHAPTER 8: RABIES VACCINE MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Serum Institute of India Pvt. Ltd.
- Sanofi
- Boehringer Ingelheim International GmbH
- Elanco Animal Health Incorporated.
- Virbac SA
- Novartis AG
- Cadila Pharmaceuticals Ltd
- Bharat Biotech International Limited
- Zoetis Inc.
- Merck & Co., Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
